|
| |
HematologicDownload PDF containing detailed information.
Recent Publications on Hematologic: |  |
Clinical study of sequential high-dose chemotherapy with in vivo rituximab-purged stem cell autografting for mantle cell lymphoma.
Sequential high-dose chemotherapy with in vivo rituximab-purged stem cell... | 6th February, 2010
| Department of Chemotherapy, Kanagawa Cancer Center.
| Rinsho Ketsueki. 2010 Jan;51(1):57-62.
|
Enhancing activity and overcoming chemoresistance in hematologic malignancies with bortezomib: preclinical mechanistic studies.
BACKGROUND: Proteasome inhibition results in antitumor activity through... | 6th February, 2010
| Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA.
| Ann Oncol. 2010 Feb 4.
DOI Direct Link |
Phase I Trial of Bortezomib and Concurrent External Beam Radiation in Patients with Advanced Solid Malignancies.
PURPOSE: To determine the maximal tolerated dose of bortezomib with... | 6th February, 2010
| Department of Radiation Oncology, University of Colorado Denver and Health
| Int J Radiat Oncol Biol Phys. 2010 Feb 2.
DOI Direct Link |
Proteasome inhibition: A new therapeutic strategy to cancer treatment.
The ubiquitin-proteasome system is a major pathway for protein... | 6th February, 2010
| Institute of Digestive Diseases, Faculty of Medicine, The Chinese
| Cancer Lett. 2010 Feb 2.
DOI Direct Link |
Hematopoietic stem cells and retroviral infection.
ABSTRACT: Retroviral induced malignancies serve as ideal models to help us... | 6th February, 2010
|
| Retrovirology. 2010 Feb 4;7(1):8.
DOI Direct Link |
→View more research publications. |
Press Releases About Hematologic:
|
 |
| AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma |
16th December, 2009 |
AETERNA ZENTARIS INC. |
Trial conducted pursuant to Special Protocol Assessment with the Food and Drug Administration
QUEBEC CITY, Dec. 16 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "
|
| Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma |
16th December, 2009 |
Keryx Biopharmaceuticals, Inc. |
NEW YORK, Dec. 16 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced today the initiation of a Phase 3 registration clinical trial for KRX-0401 (perifosine), the Company
|
| Long-Term BEXXAR(R) Data Demonstrate Overall Survival |
8th December, 2009 |
GlaxoSmithKline |
Long-term Results in both First-line and Refractory Settings Seen in Patients with Non-Hodgkin's Lymphoma
PHILADELPHIA, Dec. 8 /PRNewswire/ -- GlaxoSmithKline announced today updated long-term
|
| Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology |
7th December, 2009 |
Keryx Biopharmaceuticals, Inc. |
Evaluable
Patients CR /nCR* PR MR ORR SD**
--------- -------- -------- ------- ------- -------
All Evaluable
Patients
(n=73) 3
|
| Eleven Rigel Product Candidate Presentations at 2009 ASH Meeting |
1st December, 2009 |
Rigel Pharmaceuticals, Inc. |
SOUTH SAN FRANCISCO, Calif., Dec. 1 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that eleven presentations on preclinical studies of the company's product
|
Companies working in the area of Hematologic from Bioportfolio's Biocorporate database : | |
| Company Name | |
NeXstar Pharmaceuticals, Inc., is an integrated biopharmaceutical company engaged in the discovery, development, manufacture and marketing of proprietary pharmaceutical products to treat life...
www.nexstar.com/ View full profile
| |
Salmedix, Inc. is a San Diego-based biopharmaceutical company formed to in-license, develop and commercialize new cancer drugs, with an initial focus on hematologic cancers. Salmedix is developing...
www.salmedix.com/ View full profile
| |
Kepivance™ (palifermin) is indicated to decrease the incidence and duration of severe oral mucositis (mouth sores) in patients withhematologic (blood) cancers undergoing high-dose chemotherapy, with...
www.kepivance.com View full profile
| | →View more Hematologic related companies. |
BioPortfolio Ltd. offers e-mail and postal lists for Hematologic scientists - we have details of around 4617 individuals working on Hematologic .
This page has been viewed 353 times
Recent Search Terms used to find this page: carfilzomib PR-171 patent | Kepivance Logo | haematologic pharmaceutical products | .
Browse BioPortfolio's InDepth service - alphabetically:
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
or by Most Publications, recently searched for, or
most viewed.
Search for Hematologic across BioPortfolio, or for Hematologic Research Reports
Wikipedia excerpt, where present, licenced under the GNU Free Documentation License. Resources from the NCBI applied. Selected MeSH subject headings created and maintained by the US NLM are used in conjunction with additional keywords. 2006-2008 MeSH.
Thumbshots from Thumbshots.org
|
